| abstract |
The present invention relates to a selective androgen receptor degrader (SARD) compound and a pharmaceutical composition containing a heterocyclic ring, and prostate cancer, advanced prostate cancer, castration-resistant prostate cancer, triple negative breast cancer, androgen receptor expression For use in treating other cancers, androgenetic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA) and uterine fibroids Uses, and methods of reducing the level of androgen receptor-full length (AR-FL) in a subject, including pathogenic or resistant mutations, AR-splice variants (AR-SV) and pathogenic polyglutamine (polyQ) polymorphisms of AR. it's about |